Search results
Results From The WOW.Com Content Network
Alcon Inc. ( German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people. [2]
Calpol was launched in 1959 by English pharmaceutical company, Calmic Ltd, based in Crewe, Cheshire; the company's name was an abbreviation of Cheshire and Lancashire Medical Industries Corporation, which moved from Lancashire to Crewe Hall in 1947. The Calpol brand name is likely a combination of 'Calmic' and 'paracetamol'.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
In 2008 Nestlé sold 24.8% of existing Alcon shares to the Swiss pharmaceutical giant Novartis. In 2010 Nestlé sold the remaining 52% of its Alcon shares to Novartis. Novartis paid a total of 39.1 bn USD. Former brands. This is a selected list of the former brands formerly owned, discontinued, or sold to another company by Nestlé.
Pages in category "Pharmaceutical companies of Singapore" The following 3 pages are in this category, out of 3 total. This list may not reflect recent changes .
Location of Singapore Singapore is a sovereign island country in maritime Southeast Asia. A global city, it has a highly developed market economy, based historically on extended entrepôt trade and more recently as a financial hub as well. Its economy is known as the most freest, most innovative, most competitive, most dynamic and most business-friendly in the world by various multinational ...
As of January 2019, the Singapore Exchange (SGX) has 640 mainboard listings and 215 catalist listings.. Companies are only listed on the Singapore Exchange if they do well. If their average daily market capitalisation is less than $40 million over the last 120 market days, then it is placed on a watch-list, and if it does not improve within two years it is delisted from the Singapore Exchange.
On Jan. 4, 2010, Novartis proposed a merger of the two companies under Swiss merger law at a fixed exchange rate of 2.8 Novartis shares for each Alcon share, which would put the current value of ...